Arix IPO raises £100M for new biotech investments; Santhera sets up shop in Massachusetts
• As expected, the UK’s Arix Biosciences has raised £100 million in its IPO, which will now fuel a new round of investments in biotech companies. “We have a highly experienced international team and this new capital enables us to continue our commitment to supporting businesses in the vanguard of medical innovation, with the ultimate goal of improving outcomes for patients and unlocking value for investors,” said CEO Joe Anderson.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.